Navigation Links
New mutations in leukemia: Researchers found mechanism that can help design future therapies
Date:9/4/2011

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

Results* will be published next week in Nature Genetics and may promote the development of novel therapeutic approaches against leukemia.

The study was led by researcher Joo T. Barata at Instituto de Medicina Molecular in Lisbon, Portugal, jointly with J. Andres Yunes at Centro Infantil Boldrini in Campinas, So Paulo, Brazil, in collaboration with researchers from the National Cancer Institute in Frederick, Maryland, USA, the Erasmus Medical Center, Rotterdam, The Netherlands; and other laboratories in Europe and the US.

This is a basic research study with potential clinical impact, which was performed, in part, using samples from pediatric leukemia patients.

T-ALL affects mostly children. It is a blood cancer consisting in an uncontrolled growth in the number of T-lymphocytes (white blood cells from the immune system).

The onset of the disease can be triggered by different genetic mutations in genes involved in the proliferation and differentiation of T-cells.

The identification and study of mutations found in leukemia patients is particularly important to help develop more efficient and targeted therapies. Researchers now found a group of mutations that affect 9% of the patients with T-ALL and that may originate leukemia in these patients.

Most importantly, researchers demonstrated that a set of pharmaceutical drugs can eliminate the effect of these mutations, unraveling a potential therapeutic application for their discovery.

The current study shows that the mutations occur at the gene coding for a protein localized at the surface of T-cells, the interleukin-7 receptor (IL7R).

This protein contacts with both the exterior and the interior of the cells, acting as a bridge to transfer chemical information from the outside to the inside of cells. Information transfer occurs upon the binding of a bloodstream protein (interleukin-7) to the receptor, which triggers a cascade of cellular reactions that are essential for the correct development and proliferation of T-cells.

In the new study, researchers also found that the mutations promote non-stop, uncontrolled T-cell proliferation, independently of extracellular triggers. This capacity to induce cells to grow relentlessly is associated with the ability to originate tumors.

To help fighting the tumors that contain IL7R mutations, the team of researchers studied pharmaceutical drugs known to act in several steps of the referred cascade of cellular reactions and found that these drugs - which are already being tested against other diseases such as rheumatoid arthritis can stop cell proliferation induced in mutated cells and promote the elimination of these cells.

Says Joo T. Barata: "We discovered that the interleukin-7 receptor, which is essential for proper T-cell development, may also have a "dark side", acting as a Mr. Hyde of sorts. In particular, we found that certain mutations in this gene are involved in pediatric T-cell acute lymphoblastic leukemia and characterized how they act. Our observations allowed us to identify potential therapeutic weapons against these tumors. Although pediatric acute lymphoblastic leukemia is among the success stories in cancer therapy, improvements are still needed. We hope our findings will help further increase the efficacy and selectivity of already existing treatments."

Says J. Andrs Yunes, from Centro Infantil Boldrini in Campinas, So Paulo, Brazil: "Most mutations found resulted in the insertion of a cystein aminoacid into the IL7R. It is this new cystein that perverts the normal functioning of the receptor by linking two mutant IL7R molecules through disulfide bonds. I'm eager to know what is the probability of having a cystein codon insertion, in this specific location of the gene, to address whether this is random or not."

Says Scott K. Durum, from the National Cancer Institute in Frederick, Maryland, USA: "On the one hand, the IL-7 receptor should have seemed a likely cause of cancer because it normally stimulates cells to grow, which is what cancer cells do. On the other hand this seemed unlikely because there are normally two chains involved in signaling. However these remarkable mutations in just one of the chains circumvent the need for the second chain. In addition to existing drugs that can target this pathway, we aim to develop new antibodies against IL-7 receptor to treat these patients. "


'/>"/>
Contact: Marta Agostinho
marta-elisa@fm.ul.pt
351-918-485-068
Instituto de Medicina Molecular
Source:Eurekalert

Related biology news :

1. Mutations not inherited from parents cause more than half the cases of schizophrenia
2. Research discovers frequent mutations of chromatin remodeling genes in TCC of the bladder
3. As new data wave begins, a gene study in one disease discovers mutations in an unrelated disease
4. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
5. Environs prompt advantageous gene mutations as plants grow; changes passed to progeny
6. Mutations can spur dangerous identity crisis in cells
7. Evolutionary kings of the hill use good, bad and ugly mutations to speed ahead of competition
8. Scientists develop method to determine order of mutations that lead to cancer
9. Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal
10. UMMS researchers develop new technology to screen and analyze genetic mutations
11. Researchers link gene mutations to Ebsteins anomaly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
(Date:2/4/2016)... , Feb. 4, 2016  CytoSorbents Corporation ... leader commercializing its flagship CytoSorb® blood filter to ... patients around the world, announced that CEO Dr. ... at the Source Capital Group,s 2016 Disruptive Growth ... on the company.  Conference Presentation ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at FireflySci, ... What sets them apart from other cuvette manufacturers is their supercharged customer service ... On top of this steady flow of inside information, they have recently revamped ...
Breaking Biology Technology: